Compare PULM & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PULM | OSRH |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.5M |
| IPO Year | N/A | N/A |
| Metric | PULM | OSRH |
|---|---|---|
| Price | $4.43 | $0.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.5K | ★ 10.2M |
| Earning Date | 10-16-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $134.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.90 | $0.45 |
| 52 Week High | $10.40 | $12.54 |
| Indicator | PULM | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 44.48 |
| Support Level | $3.95 | $0.63 |
| Resistance Level | $4.48 | $0.77 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 50.96 | 0.00 |
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.